SOD1 and Parkinson disease: ApoAI MP can increase SOD, CAT, GSH-Px activity, up-regulate GSH content, and reduce the level of malondialdehyde, a marker of lipid peroxidation; and it was suggested that the therapeutic mechanism of ApoAI MP on PD may be related to alleviating oxidative stress and reducing the damage of ROS and H2O2.